Exhibit 99.1

Apollo Medical Holdings September 2023 Powered by Technology. Built by Doctors. For Patients.

This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the Compa ny's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, integratio n o f acquired companies and any projections of earnings, revenue, EBITDA, Adjusted EBITDA or other financial items, such as the Company's p roj ected capitation and future liquidity, and may be identified by the use of forward - looking terms such as “anticipate,” “could,” “can,” “may,” “might,” “potential,” “predict,” “should,” “estimate,” “expect,” “project,” “believe,” “plan,” “envision,” “intend,” “continu e,” “target,” “seek,” “will,” “would,” and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. Forward - looking statements reflect current views with respect to future events and financial performance and theref ore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's manageme nt, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actua l r esults may also vary materially from forward - looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company’s reports to the U.S. Securities and Exchange Commission (the “SEC”), incl udi ng without limitation the risk factors discussed in the Company's Annual Report on Form 10 - K/A for the year ended December 31, 2022 , and subsequent Quarterly Reports on Form 10 - Q. Because the factors referred to above could cause actual results or outcomes to differ materially from those expressed or imp lie d in any forward - looking statements, you should not place undue reliance on any such forward - looking statements. Any forward - looking statements speak only as of the date of this presentation and, unless legally required, the Company does not undertake any ob lig ation to update any forward - looking statement, as a result of new information, future events or otherwise. Forward - looking statements 2

3 ApolloMed is a technology - powered, value - based healthcare platform that enables the delivery of high - quality, coordinated, efficient, and accessible care for all through the following business segments: Care Enablement delivers an integrated clinical and administrative platform to enable payers and providers in the delivery of high - quality, value - based care. Care Partners enables aligned providers to participate in high - performing, risk - bearing organizations. Care Delivery provides patient - centric clinical operations, including primary care, multi - specialty, and ancillary services. ApolloMed At - A - Glance Ticker NASDAQ: AMEH Headquarters Alhambra, California Recent Stock Price (as of 9/8/2023) $33.24 Market Cap (as of 9/8/2023) $1.9 billion Common Shares Outstanding* (as of 8/1/2023) 57.6 million Book Value Per Common Share $9.94 *Includes 10.6 million in treasury shares Information as of 6/30/2023 unless otherwise noted 26% Revenue Growth CAGR from 2019 - 2023E $146M TTM Adj. EBITDA 1 61% lower than CMS benchmark for Medicare Advantage ER visits/K 2 $1.30B TTM Revenue 1 ( 1 ) TTM ended June 30 , 2023 . For more information, see “ TTM and Year - end Reconciliation of Net Income to EBITDA and Adjusted EBITDA ” and “Use of Non - GAAP Financial Measures “ slides for more information ( 2 ) Across all consolidated ApolloMed IPAs for Medicare Advantage, benchmarks derived from CMS data Company overview

(1) Medicare Advantage, Managed Medicaid, Commercial, ACA Exchange, and Medicare FFS (2) ApolloMed 2019 to 2023E revenue and adj. EBITDA growth, using midpoint of 2023 guidance for both metrics. Please refer to th e “2023 Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “Use of Non - GAAP Financial Measures” slides for more information. 4 1. 2. 3. 5. 6. 4. Accelerating high quality, accessible, value - based care across all patient populations 1 Inflecting in both growth and profitability: 4 - year CAGR (2019 - 2023E) 2 for revenue of 26% and for adj. EBITDA of 27% Scalable approach that empowers entrepreneurial providers to deliver value - based care and industry - leading outcomes Purpose - built technology platform leveraging 25+ years of real - world clinical data Profitable , highly replicable unit economics Estimated TAM of $2T , with ApolloMed presence growing across 30 markets and counting ApolloMed investment highlights

64% 20% 12% 4% Medicare Medicaid Commercial Other third parties Longstanding R elationships with N ational and L ocal P ay e rs + Many more payers 2019 2020 2021 2022 2023 Revenue 1 Average tenure: ~15 years 88% 5% 3.3% 3.7% Capitation Risk pool settlements & incentives Management fee income Fee-for-service Other Revenue by Payer Type 2 Revenue by Line of Business 2 $561M $687M $774M $1,300M - $1,500M 26% CAGR 5 We have laid a solid foundation for rapid growth $1,144M Adjusted EBITDA 1 2019 2020 2021 2022 2023E 27% CAGR $54M $103M $134M $120M - $160M $140M Source: Internal data; (1) Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, exc luding income or loss from equity method investments, non - recurring transactions, stock - based compensation, and APC excluded assets costs. Beginning the third quarter en ded September 30, 2022, the Company revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business. Please refer to the “TTM and Year - end Reconciliation of Net Income to EBITDA and Adjusted EBITDA” and “2023 Guidance R econciliation of Net Income to EBITDA and Adjusted EBITDA” slides for more information. (2) Figures for six months ended 6/30/2023. 0.5%

Payer agnostic platform captures outsized TAM and delivers better experience for patients, providers, and payers Source: CMS and HCP - LAN (2021) 6 Be tter for patients Enhanced patient experience and care continuity across payer, plan, and stage of life Better for providers Can be empowered across their entire panel via ApolloMed platform Better for payers Can partner with ApolloMed across all their lines of business ~$340B+ Medicaid ~$700B+ Commercial ~$920B+ Medicare ~$2T

VBC infrastructure and tech stack drives highly replicable and scalable results across all patients, allowing providers to grow and succeed across value - based arrangements • 1.3M patients managed in value - based contracts 1 • We serve Medicare Fee - for - Service (Original Medicare), Medicare Advantage (MA), Medicaid, and Commercial patients All Provider Partners • 12,000+ contracted providers in our physician network across all specialties • Our partners include clinics, hospitals, ASCs, SNFs, UCs, labs, and diagnostics centers 2 All Payment Arrangements • Tech platform supports capitation, shared savings, FFS and other flexible value - based arrangements • 20+ payer partners, with an average partnership of ~15 years • Care Enablement: integrated end - to - end clinical and administrative platform • Care Delivery: a patient - centric care delivery organization • Care Partners: enables aligned providers in their path towards value - based care We are radically transforming how care is delivered at scale, serving… (1) As of 6/30.2023 (2) ASC is ambulatory surgical center, i.e., outpatient procedures; SNF is skilled nursing facility; UC is urgent care 7 All Modalities All Patients

Providers currently face complex administrative and care coordination hurdles Reporting Contracting Claims Data Aggregation Billing Coding Hospitals Clinics Referrals Authorization Clearinghouse IT Credentials Quality Providers PR Labs Many More Payers Diagnostics ? 8

ApolloMed acts as a “single payer,” connects health ecosystem participants, and integrates clinical, tech, and administrative support for providers 9 ApolloMed is paid to assume risk for the care of our patients 1 We reimburse providers in a subscription model and share savings, aligning incentives 3 We build high - quality networks and enable providers via our care teams and technology platform 2 Care Enablement ApolloMed acts as single payer Providers paid via VBC contracts + Many More Payers Care Partners ACO Network Independent Physician Associations and Networks Restricted Knox Keene License Specialists Ancillary Primary Care Providers Care Delivery Patient

Care Partners ACO Network Independent Physician Associations and Networks Restricted Knox Keene License 10 Specialists Ancillary Primary Care Providers Care Delivery Care Delivery provides high quality and accessible health care services through a patient - centric care delivery organization, including primary care, multi - specialty, and ancillary services. Care Partners enables aligned providers in their path towards value - based care, improving access, quality, and outcomes. Care Enablement delivers an integrated end - to - end clinical and administrative platform that enables payers and providers in the delivery of high quality, value - based care. Patient ApolloMed segments enable our mission to deliver high quality, coordinated care to all Care Enablement

Care Partners ACO Network Independent Physician Associations and Networks Restricted Knox Keene License 11 Specialists Ancillary Primary Care Providers Care Delivery Patient Care Enablement Contracting & Credentialing Revenue Cycle Authorization Provider Relations UM 1 & Care Management Clinical Programs Remote Patient Monitoring Quality Analytics & Reporting Point of Care Tool VBE Suite & Data Lake Ops Automation The ApolloMed care enablement model seamlessly wraps around our providers’ operations, empowering them to thrive in value - based care arrangements We build high quality specialist and facility networks around our PCPs 1 2 3 4 Our providers leverage ApolloMed’s scaled, seamless administrative solutions Coordinated care teams create unified care plans for patients and support them throughout healthcare journey Our technology suite provides an interoperable, best - in - class experience 1 2 3 4 (1) Utilization Management

We are changing healthcare through a physician - centric approach that provides flexibility and scale for our providers Industry Status Quo ApolloMed Patients supported throughout care journey by our ecosystem and care teams Entrepreneurial physicians can remain independent and partner with ApolloMed Capitated reimbursement and value - based incentives with ApolloMed as payer Data aggregated onto interoperable platform; providers leverage ApolloMed tech - suite Physicians can support patients through different life stages and payer choices No unified care plan for patients across multiple visits to a fragmented healthcare system Physicians must choose to be employed or tackle administrative functions alone Complex reporting requirements and incongruous incentives from different payers Many different tech stacks and non - interoperable point solutions Physicians can only serve limited patients 12

Our platform is powered by our proprietary technology suite, connecting patients, providers, and payers Provider Point of Care Application EHR 1 Data Patient Care Management ApolloMed Care Team CM/DM, PAC, SDoH , etc. 3 Communications Patient Management / RPM / Real - Time Clinical AI Care Mgmt / Workflow Tools Eligibility & Benefits Claims Adjudication Prior Authorization ApolloMed Payer Tools Other Clinical Inputs Clinic Setting ~100% automated ~70% automated ~90% automated ApolloMed Value - Based Enablement (VBE) Suite Care Plans Transition of Care Preventive Care Alerts & Analytics Notes ADT 2 Alerts Diagnostics Lab Results RPM Survey Results 2 1 (1) EHR: Electronic Health Record (2) ADT: Admission, Discharge, and Transfer (3) CM: Care Management, DM: Data Management, PAC: Post Acute Care, SDoH : Social Determinants of Health 13

ApolloMed creates a flywheel powered by deep experience, an extensive provider network, and proprietary technology Providers will succeed in value - based arrangements with ApolloMed Personalized & effective care will engage patients and lower the total cost of care Improved care pathways and predictive models serve the unique needs of the communities we serve Ongoing investment in technology and analytics capabilities Patient growth allows for greater investment in resources to support patients Existing providers will continue to grow with ApolloMed, and our success will attract more like - minded physicians to our platform Our flywheel drives sustainable growth & entrenches us as the platform of choice for providers, payers and patients 14

ApolloMed is growing in 30+ markets in 8 counties across 3 states 15 Served by ApolloMed’s Care Partners (IPAs, ACO), Care Delivery, and Care Enablement Served by ApolloMed’s Care Partners (ACO) and Care Enablement New CA San Francisco San Mateo Nevada Clark Texas Tarrant Harris Core CA Los Angeles San Bernardino Riverside Our scaling footprint Investing in diversified lines of business Primary care centric networks surrounded by high quality specialists Meeting providers where they are in their progression towards value via Care Enablement, Care Partners, and Care Delivery businesses

Two clear levers combine to drive rapid growth Data as of Q3 2022; (1) Note that in CA markets we have capability to more quickly accelerate new patients along risk ladder, an d start patients beyond PCP Cap Only; (2) Increasing risk in value - based contracts corresponds to larger opportunity size in value - based care Lower risk ($) Higher risk 2 ($) Members by risk type and geography Core CA New CA Ex - CA FFS PCP Cap Only 1 Professional Risk Full Risk Global Risk 500K+ N/A 250K – 500K 250K – 500K 10K – 100K 500K+ N/A 5K – 10K 5K - 10K <5K 500K+ <5K N/A N/A N/A Increasing risk in value - based contracts Take more risk and manage to great clinical outcomes Expanding membership Develop clinical excellence and local scale to attract membership Core CA Securing nationwide payer contracts and establishing local provider partnerships Ex - CA Extending our specialist and facility partnerships around existing anchor PCP groups Leveraging our dense, high quality provider network and best - in - class facilities New CA Membership expansion drivers 16

Multi - faceted growth strategy across our markets Where we are today Growth strategy Recent developments Core CA New CA Ex - CA x 5 counties across core CA geographies x Extensive and long - standing provider network x 80% member growth since acquisition x Provider count increased by 110% x 58% increase in value - based c ontracts 3 x Average 4.7 - stars over 361 Google reviews x Added 30k members in new CA counties x Added 92 0 new providers • Move toward global risk with RKK 1 • Leveraging MSO relationships and contracting new providers • Accretive tuck - ins • P rimary care groups in M&A pipeline • Deepen broker relationships • Growing specialist and hospital networks • De novo clinic expansion • Move toward global risk with RKK 1 • Expand institutional and specialist partnerships • Growth with new and existing payers • Tuck - ins Opened multip le multi - specialty supercenters 20% growth 2 in contracted providers YoY PROVIDER PARTNERSHIPS PROVIDER PARTNERSHIPS ADDED PAYER PARTNERS ADDED STATES NV TX Data as of December 2022; (1) RKK is a Restricted Knox - Keene license. The RKK License permits an Entity to enter into global ris k arrangements with fully licensed health plans on a contract - by - contract basis. For more information on the impact of RKK, please refer to the “Path to Global Risk” section of the appendix; (2) For core CA region IPAs Dec 2021 – Dec 2022, which include Allied Pacific IPA, Accountable Health Care IPA, and Alpha Care Medical Group; (3) Value Based Contracts con sist of managed care, shared risk agreements, capitated shared risk, commercial capitation, Medicare Advantage, surplus and incentive programs 17

Consistent clinical outcomes across diverse populations and demographics Medicare Advantage and ACO Clinical Outcomes Purpose - built technology platform enables best - in - class clinical outcomes to be delivered for all Americans Ethnicities Served 5 48% 21% 12% 6% 13% (1) Figures based on analysis of Jan - Sept 2022 internal data from all consolidated IPAs; (2) 2022 GPDC ACO Model, figures based on analysis of internal data from Jan - Sept 2022; (3) Centers for Medicare and Medicaid Services, Office of Enterprise Data and Anal ytics, CMS Chronic Conditions Data Warehouse; (4) Agency for Healthcare Research and Quality (Department of Health and Human Services); (5) Ethnicities of members across all IPAs, based on analysis of internal data from Dec 2022; (6) Asian American and Pacific Isla nde r Hispanic / Latino AAPI 6 White / Caucasian Black / African American Other Medicare Advantage 1 727 54% 3 Lower than benchmark 194 61% 3 Lower than benchmark 6.3% 63% 4 Lower than benchmark ACO 2 751 53% 3 Lower than benchmark 328 34% 3 Lower than benchmark 8.2% 52% 4 Lower than benchmark Inpatient Bed Days / K ER Visits / K Readmission Rate 18

10% - 17% adj. EBITDA margins over the last 4 years 2 Bed days 54% below benchmark; ER visits 61% below benchmark 3 1.3M members in VBC arrangements across Medicare, Medicaid, and Commercial 4 27% 4 - year EBITDA CAGR with 15% EBITDA margins at scale Key takeaways Strongly positioned to create a future where all can get access to high quality healthcare Proven track record of consistent profitability Our tech - powered, integrated care delivery model results in industry - leading clinical outcomes Flexible, capital efficient model with predictable unit economics Clear levers and a repeatable growth playbook to drive further nationwide expansion (1) Growth figures are based on historical revenue and estimates through FY 2023 (2) See the “TTM and Year - end Reconciliation of Net Income to EBITDA and Adjusted EBITDA” slide for additional information. (3) Across all consolidated ApolloMed IPAs for Medicare Advantage, benchmarks derived from CMS data (4) As of 6/30/2023 26% 4 - year revenue CAGR with clear visibility into continued 25%+ growth 1 19

Appendix

Financial Data

561 687 774 1144 1300 - 1500 2019 2020 2021 2022 2023E We have a strong track record of revenue growth and a robust EBITDA profile ($ in millions) Revenue 26% CAGR ($ in millions) Adjusted EBITDA 1 27% CAGR Source: Internal data; (1) Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, exc luding income or loss from equity method investments, non - recurring transactions, stock - based compensation, and APC excluded assets costs. Beginning the third quarter ended September 30, 2022, the Company revised the calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more reflective of its business. Please refer to the “2023 Guidance Reco nci liation of Net Income to EBITDA and Adjusted EBITDA,” “TTM and Year - end Reconciliation of Net Income to EBITDA and Adjusted EBITDA,” and “Use of Non - GAAP Financial Measures” slides for more information. 54 103 134 140 120 - 160 2019 2020 2021 2022 2023E Membership 9% CAGR 1.0 1.1 1.2 1.3 2019 2020 2021 2022 (millions) 22

ApolloMed is a scaled player with a proven and profitable model Business Model 1 Affiliate - provider model Affiliate - provider model Affiliate - provider model Affiliate - provider Model Affiliate - provider model Members Served 1.3M 2 1.1M 3 495.9k 4 272.5k 5 104.1k 6 Serves All Patient Types 1, 7 P P O O O Market Capitalization 8 $1.9B $3.0B $7.5B $248.8M $659.7M 2023E Revenue 9 $1,300M - $1,500M 10 $1,600M 3 $4,532.5M 4 $775M 5 $1,225M 6 2023E Adj. EBITDA 9 $120M - $160M 11 $72M 3 $11.5M 4 $30M 5 ($40M) 6 (1) Based on recent company filings or investor presentations; (2) As of 6/30/2023; (3) Privia Health Q2 2023 Earnings Release (August 2023); (4) agilon health Q2 2023 Earnings Release (August 2023); (5) CareMax Q2 2023 Earnings Release (August 2023); (6) P3 Health Partners Form 10 - Q and Q2 2023 Earnings Release (August 2023); (7) Patient ty pes include Medicare (incl. Medicare Advantage), Medicaid, and Commercial members; (8) Diluted shares outstanding as of Q2 2023 10 - Qs, stock prices used to calculate market cap as of 9/8/23; (9) Peer 2023E Reven ue and Adj. EBITDA based on midpoint of company provided guidance; (10) ApolloMed 2023E Revenue as reported in its Q2 2023 earnings release; (11) Please refer to the “2023 Guidance Reconciliation of Net Inco me to EBITDA and Adjusted EBITDA” and “Use of Non - GAAP Financial Measures” slides for more information. 23

ApolloMed is working to scale its three business segments: Care Enablement, Care Partners, and Care Delivery 24 For the three months ended June 30, 2023 (1) Balance includes general and administrative expenses and depreciation and amortization . (2) Income from operations for the intersegment elimination represents rental income from segments renting from other segments. R ent al income is presented within other income, which is not presented in the table. $ in 000s Care Enablement Care Partners Care Delivery Other Intersegment Elimination Corporate Costs Consolidated Total Total revenues $ 34,975 325,246 26,718 157 (38,887) - 348,209 % change vs prior year quarter 18% 31% 14% 29% Cost of services 15,162 292,119 22,523 70 (36,988) - 292,876 General and administrative expenses (1) 12,175 5,298 3,626 926 (2,933 ) 9,212 28,304 Total expenses 27,337 297,417 26,149 996 (39,931) 9,212 321,180 Income (loss) from operations $ 7,638 27,829 569 (839) 1,044 (2) (9,212) 27,029 % change vs prior year quarter 4% 250% (82%) 76%

2023 Guidance ($ in millions, except for per share information) Actual YE 2022 Results 2023 Guidance Range Total Revenue $1,144.2 $1,300.0 - $1,500.0 Net Income 1 $50.5 $49.5 - $71.5 EBITDA 1,2 $110.1 $89.5 - $129.5 Adjusted EBITDA 2 $140.0 $120.0 - $160.0 EPS - Diluted $1.08 $0.95 - $1.20 (1) Net income and EBITDA forecast includes the impact of APC excluded assets, which assumes no change in value. (2) See “Reconciliation of Net Income to EBITDA and Adjusted EBITDA (Q2 2023)”, “2023 Guidance Reconciliation of Net Income t o E BITDA and Adjusted EBITDA” and “Use of Non - GAAP Financial Measures” slides for more information. There can be no assurance that actual amounts will not be materially higher or lower than these expectation s. See “Forward - Looking Statements” on slide 2. 25

2023 Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA ($ in millions) Low High Net income $ 49.5 $ 71.5 Interest expense 1.0 1.0 Provision for income taxes 23.0 38.0 Depreciation and amortization 16.0 19.0 EBITDA 1 $ 89.5 $ 129.5 Loss (income) from equity method investments $ (0.8) $ (0.8) Other, net 3.3 3.3 Stock-based compensation 16.0 16.0 APC excluded assets costs 12.0 12.0 Adjusted EBITDA 1 $ 120.0 $ 160.0 Year Ending December 31, 2023 (1) See “Use of Non - GAAP Financial Measures” slide for more information. 26

Reconciliation of Net Income to EBITDA and Adjusted EBITDA (Q2 2023) ($ in millions) 2023 2022 (restated) 2023 2022 (restated) Net income $ 17.5 $ 11.3 $ 30.0 $ 22.7 Interest expense 3.6 1.9 6.9 2.9 Interest income (3.3) (0.4) (6.3) (0.5) Provision for income taxes 14.0 5.4 20.9 12.2 Depreciation and amortization 4.2 4.4 8.5 8.7 EBITDA (1) $ 36.0 $ 22.4 $ 60.0 $ 46.1 Income from equity method investments $ (0.3) $ (0.2) $ (0.5) $ (0.3) Other, net (2) (1.6) - (0.2) - Stock-based compensation 4.2 3.9 7.7 7.0 APC excluded assets costs (2.6) (1.2) (1.3) 6.5 Adjusted EBITDA (1,3) $ 35.8 $ 24.9 $ 65.6 $ 59.3 Three Months Ended June 30, Six Months Ended June 30, (1) See “Use of Non - GAAP Financial Measures” slide for more information (2) Other, net for the three and six months ended June 30, 2023, relates to non - cash changes in the fair value of the Company’s fina ncing obligations to purchase the remaining equity interest, changes in the fair value of its contingent liabilities, and changes in the fair value of the Company’s Collar Agreement. (3) Adjusted EBITDA under the historical method for the three and six months ended June 30, 2022, was $36.9 million and $75.1 mil lio n, respectively. See “Use of Non - GAAP Financial Measures” slide for additional information on change of methodology. 27

TTM and Year - end Reconciliation of Net Income to EBITDA and Adjusted EBITDA ($ in millions) TTM ended June 30, 2023 2022 2021 2020 2019 Net income $ 53.0 $ 45.7 $ 46.1 $ 122.1 $ 15.8 Interest expense 11.9 7.9 5.4 9.5 4.7 Interest income (7.8) (2.0) (1.6) (2.8) (2.0) Provision for income taxes 49.6 40.9 31.7 56.3 10.0 Depreciation and amortization 17.4 17.5 17.5 18.4 18.3 EBITDA (1) $ 124.0 $ 110.1 $ 99.1 $ 203.5 $ 46.8 Goodwill impairment - - - - 2.0 Income from equity method investments (1.0) (0.7) (0.3) (0.0) 0.2 Gain on sale of equity method investment - - (2.2) - - Other, net 3.1 (2) 3.3 (3) (1.7) (4) (0.5) (4) - Stock-based compensation 16.8 16.1 6.7 3.4 0.9 APC excluded assets costs 3.4 11.3 31.9 (103.6) 4.3 Adjusted EBITDA (1) $ 146.4 $ 140.0 $ 133.5 $ 102.8 $ 54.2 Net revenues $ 1,296.7 $ 1,144.2 $ 773.9 $ 687.2 $ 560.6 EBITDA margin (5) 9.6% 9.6% 12.8% 29.6% 8.3% Adjusted EBITDA margin (5) 11.3% 12.2% 17.3% 15.0% 9.7% Year Ended December 31, (1) See “Use of Non - GAAP Financial Measures” slide for more information (2) Other, net for TTM ended June 30, 2023, relates to transaction costs incurred in the second half of 2022 and non - cash changes in the fair value of the Company’s financing obligations to purchase the remaining equity interest, changes in the fair value of its contingent liabilities, and changes in the fair value of the Comp any ’s Collar Agreement. (3) Other, net for the year ended December 31, 2022, relates to transaction costs incurred and changes in the fair value of our m and atory purchase of investments and contingent considerations. (4) Other, net for the years ended December 31, 2021 and 2020 relate to COVID - 19 relief payments recognized in 2021 and 2020. (5) EBITDA margin is defined as EBITDA divided by net revenues. Adjusted EBITDA margin is defined as adjusted EBITDA divided by n et revenues. 28

Summary of Selected Financial Results – Breaking Out Excluded Assets 29 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 $ in millions ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets Revenue Capitation, net $ 600.8 - 600.8 $ 449.7 - 449.7 Risk pool settlements and incentives 33.6 - 33.6 36.9 - 36.9 Management fee income 22.4 - 22.4 20.5 - 20.5 Fee - for - service, net 25.3 - 25.3 22.8 - 22.8 Other income 3.4 - 3.4 3.1 - 3.1 Total revenue 685.5 - 685.5 533.0 - 533.0 Total operating expenses 636.0 1.3 634.8 491.3 1.6 489.7 Income (loss) from operations 49.4 (1.3) 50.7 41.7 (1.6) 43.3 Total other income (expense), net 1.5 2.1 (0.6) (6.7) (8.5) 1.8 Net income (loss) $ 30.0 0.9 29.1 $ 22.8 (10.1) 32.9 (1) Includes APC Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns th e a sset but not the right to the dividends associated with those assets.

Summary Balance Sheet – Breaking Out Excluded Assets 30 (1) Includes APC Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns th e a sset but not the right to the dividends associated with those assets. $ in millions ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets Current assets Cash and cash equivalents $ 294.2 13.1 281.1 $ 288.0 30.2 257.8 Investments in marketable securities 3.8 1.1 2.7 5.6 4.5 1.1 Receivables, net 66.9 - 66.9 49.6 - 49.6 Receivables - related parties and loan receivable - related party 82.8 - 82.8 67.2 - 67.2 Other receivables, prepaid expenses and other current assets 17.3 1.2 16.1 17.6 0.8 16.8 Income taxes receivable - - - - (1.1) 1.1 Total current assets 465.0 15.4 449.6 428.0 34.4 393.6 Non-current assets Land, property, and equipment, net 123.9 116.9 7.0 108.5 101.3 7.2 Goodwill and intangibles 348.4 - 348.4 346.0 - 346.0 Loan receivable and loan receivable - related parties, net of current portion - - - - - - Income taxes receivable, non-current 15.9 - 15.9 15.9 - 15.9 Investments in other entities and privately held entities 48.7 32.2 16.5 41.2 27.6 13.6 Other assets and right-of-use assets 25.1 4.2 20.9 26.5 3.2 23.3 Total non-current assets 562.0 153.3 408.7 538.1 132.1 406.0 Total assets $ 1,027.0 168.7 858.3 $ 966.1 166.5 799.6 June 30, 2023 December 31, 2022

Summary Balance Sheet – Breaking Out Excluded Assets (continued) 31 $ in millions ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets Current liabilities Fiduciary payable, accounts payable and accrued liabilities $ 58.5 0.7 57.8 $ 57.7 2.8 54.9 Medical liabilities 100.0 - 100.0 81.3 - 81.3 Income taxes payable 19.6 1.1 18.5 4.3 - 4.3 Dividend payable 0.6 - 0.6 0.7 - 0.7 Finance and operating lease liabilities 3.6 0.1 3.5 4.2 - 4.2 Current portion of long-term debt 2.6 0.6 2.0 0.6 0.6 - Total current liabilities 184.9 2.5 182.4 148.8 3.4 145.4 Non-current liabilities Deferred tax liability 12.4 0.9 11.5 14.2 0.9 13.3 Finance and operating lease liabilities, net of current portion 19.0 0.90 18.1 21.2 - 21.2 Other long-term liabilities 21.4 - 21.4 20.3 - 20.3 Long-term debt, net of current portion and deferred financing costs 205.1 27.9 177.2 203.4 26.6 176.8 Total non-current liabilities 257.9 29.7 228.2 259.1 27.5 231.6 Total liabilities 442.8 32.2 410.6 407.9 30.9 377.0 Total mezzanine equity and stockholder's equity $ 584.2 136.5 447.1 $ 558.2 135.6 422.6 June 30, 2023 December 31, 2022 (1) Includes APC Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns th e a sset but not the right to the dividends associated with those assets.

Summary Statement of Cash Flows – Breaking Out Excluded Assets 32 $ in millions ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets Cash flows from operating activities Net income $ 30.0 0.9 29.1 $ 22.7 (10.1) 32.8 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization $ 8.5 0.8 7.7 $ 8.7 0.5 8.2 Amortization of debt issuance cost 0.5 - 0.5 0.5 - 0.5 Share-based compensation 7.7 - 7.7 7.0 - 7.0 Unrealized loss on investments 5.5 3.5 2.0 13.7 11.3 2.4 Gain on sales of investment - - - (2.3) - (2.3) Loss (income) from equity method investments, net (5.2) (4.7) (0.5) (2.9) (0.1) (2.8) Unrealized gain on interest rate swaps - - - (2.8) (2.8) - Deferred tax (3.7) - (3.7) 3.4 - 3.4 Changes in operating assets and liabilities, net of acquisition amounts: Receivables, net, receivable, net - related parties, other receivable, prepaid expenses and other current assets, right of use assets, other assets, fiduciary accounts payable, medical liabilities, and operating lease liabilities (22.4) (0.5) (21.9) (15.1) 0.7 (15.8) Accounts payable and accrued liabilities (2.9) (2.1) (0.8) 14.2 (0.1) 14.3 Income taxes payable 15.3 - 15.3 (14.0) - (14.0) Net cash provided by (used in) operating activities $ 33.3 (2.1) 35.4 $ 33.1 (0.6) 33.7 June 30, 2022June 30, 2023 (1) Includes APC Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns th e a sset but not the right to the dividends associated with those assets.

Summary Statement of Cash Flows – Breaking Out Excluded Assets (continued) 33 $ in millions ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets ApolloMed Consolidated Excluded Assets (1) ApolloMed Assets Cash flows from investing activities Payments for business and asset acquisition, net of cash acquired $ 0.4 - 0.4 $ (0.9) - (0.9) Proceeds from repayment of loans receivable - related parties 2.1 - 2.1 4.0 4.0 - Purchase of marketable securities (2.0) - (2.0) $ (1.8) - (1.8) Purchase of investments - privately held (2.0) - (2.0) - - - Purchase of investments - equity method (0.3) - (0.3) - - - Proceeds from sale of marketable securities - - - 6.5 (0.1) 6.6 Distribution from investments - equity method - - - 0.4 0.4 - Contribution to investment - equity method - - - (1.7) (1.7) - Purchases of property and equipment (17.4) (16.4) (1.0) (18.8) (17.8) (1.0) Net cash (used in) provided by investing activities (19.2) (16.4) (2.8) (12.3) (15.2) 2.9 Cash flows from financing activities Dividends paid $ (0.8) - (0.8) $ (12.6) (10.0) (2.6) Repayments on long-term debt (0.3) (0.3) - (0.2) (0.2) - Payment of finance lease obligations (0.3) - (0.3) (0.3) - (0.3) Proceeds from exercise of stock options and warrants 1.3 - 1.3 1.7 - 1.7 Repurchase of common stock - - (9.5) - (9.5) Repurchase of treasury shares (9.5) - (9.5) - - - Purchase of non-controlling interest (0.1) - (0.1) (0.2) - (0.2) Proceeds from sale of non-controlling interest - - - - - - Borrowings on loans 1.7 1.6 0.1 1.2 0.6 0.6 Amounts due from affiliates - - - - (16.6) 16.6 Net cash (used in) provided by financing activities $ (8.0) 1.3 (9.3) $ (19.9) (26.2) 6.3 Net change in cash and cash equivalents 6.1 (17.2) 23.3 1.1 (41.9) 43.0 Cash and cash equivalents at beginning of period $ 288.0 30.2 257.8 $ 233.1 62.5 170.6 Cash and cash equivalents at end of period $ 294.1 13.0 281.1 $ 234.2 20.6 213.6 June 30, 2022June 30, 2023 (1) Includes APC Excluded Assets and certain other assets such as APC's minority interests in LMA and PMIOC where APC owns th e a sset but not the right to the dividends associated with those assets.

Path to Global Risk

We believe our ability to succeed at managing care across our outpatient and inpatient risk contracts allows us to capture significantly more upside than our peers (1/2) Facility / Hospital Outpatient Total Premium Dollar ApolloMed EBITDA from VBC We have an integrated inpatient - outpatient system featuring hospital partners, ADT feeds, and care coordination, all facilitated by our tech - enabled platform, resulting in industry - leading cost efficacy 2 1 2 Health plan Our community - based providers, vertically - integrated health services network, and population health efforts drive down claims PMPM vs peers 1 1 1 (1) Operating expenses excluding interest, tax, depreciation, and amortization 1 35

Facility / Hospital Outpatient Total Premium Dollar Health plan We reduce administrative costs using our MSO’s proprietary automation tools — this allows us to profitably scale, enhancing operating leverage 3 1 1 1 VBE Rev COGS OpEx VBE EBITDA 3 3 Mgmt. Income from Non - Consolidated IPAs (1) Operating expenses excluding interest, tax, depreciation, and amortization 36 We believe our ability to succeed at managing care across our outpatient and inpatient risk contracts allows us to capture significantly more upside than our peers (2/2)

We see a clear path to success as we continue to move our existing contracts along the risk spectrum and expect to do so in new markets as well FFS Professional Full Risk Global 37

A significant part of our revenue today is generated by capitation from our professional risk contracts FFS Professional Full Risk Global 1 (1) Operating expenses excluding interest, tax, depreciation, and amortization 38

We also receive additional revenue and upside from full risk contracts that we share with our facility partners FFS Professional Full Risk Global Facility / Hospital Outpatient ApolloMed EBITDA from VBC Health plan 1 1 1 Total Premium Dollar VBE Rev COGS OpEx VBE EBITDA Mgmt. Income from Non - Consolidated IPAs (1) Operating expenses excluding interest, tax, depreciation, and amortization 39

With an RKK, we believe we will be able to manage the whole professional and facility risk capitation dollar and achieve more downstream synergies and upside FFS Professional Full Risk Global Total Premium Prof. + Facility Cap Medical Expense Overhead EBITDA from VBC VBE Rev COGS OpEx VBE EBITDA Plan Sub - cap Prof. + Facility Cap LT Margin 10 - 20% LT Margin 20 - 30% LT Margin 10 - 20% LT Combined EBITDA Mgmt. Income from Non - Consolidated IPAs 1 (1) Operating expenses excluding interest, tax, depreciation, and amortization 40

Key acronyms ◦ ACO: Accountable Care Organization ◦ ACO REACH: Accountable Care Organization Realizing Equity, Access, and Community Health ◦ AIPBP: All - Inclusive Population - Based Payments ◦ APC: Allied Physicians of California IPA ◦ CMMI: Center s for Medicare and Medicaid Innovation Center ◦ CMS: Centers for Medicare and Medicaid Services ◦ DC: Direct Contracting ◦ DCE: Direct Contracting Entity ◦ DME: Durable Medical Equipment ◦ Health Plan / Pay e rs: Health Insurance Companies ◦ HMO: Health Maintenance Organization ◦ IPA: Independent Practice Association ◦ NCI: Non - Controlling Interest ◦ NMM: Network Medical Management , Inc. ◦ MSA: Master Service Agreement ◦ MSO: Management Services Organization ◦ NGACO: Next Generation Accountable Care Organization ◦ PCP: Primary Care Physician ◦ PMPM: Per Member Per Month ◦ SNF: Skilled Nursing Facility ◦ VIE: Variable Interest Entity ◦ RKK: Restricted Knox - Keene 41

Use of Non - GAAP Financial Measures This presentation contains the non - GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable fin ancial measure presented in accordance with U.S. generally accepted accounting principles (“GAAP”) is net income. These measures are no t in accordance with, or alternatives to, GAAP, and may be calculated differently from other non - GAAP financial measures used by other companies . The Company uses Adjusted EBITDA as a supplemental performance measure of its operations, for financial and operational decision - making, and as a supplemental means of evaluating period - to - period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings b efore interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non - recurring transactions, stoc k - based compensation, and APC excluded assets costs. Beginning in the third quarter ended September 30, 2022, the Company has revised th e calculation for Adjusted EBITDA to exclude provider bonus payments and losses from recently acquired IPAs, which it believes to be more r efl ective of its business. The Company believes the presentation of these non - GAAP financial measures provides investors with relevant and useful informati on, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recogniz ed because of non - core or non - recurring financial information. When GAAP financial measures are viewed in conjunction with non - GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance. In addition, these non - GAAP financ ial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and plan nin g and forecasting future periods. Non - GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financi al measures. To the extent this release contains historical or future non - GAAP financial measures, the Company has provided corresponding GAAP finan cial measures for comparative purposes. The reconciliation between certain GAAP and non - GAAP measures is provided above. 42

43 For inquiries, please contact: ApolloMed Investor Relations (626) 943 - 6491 investors@apollomed.net Carolyne Sohn, The Equity Group (408) 538 - 4577 csohn@equityny.com